Study · Randomized controlled trial · n = 3,533 · 2024

7 results

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R

The New England journal of medicine24 May 2024Cited by 1,523 (Europe PMC)

PMID38785209DOI10.1056/nejmoa2403347PepBankPUB-38785209

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and chronic kidney disease, the risk of major kidney disease events was 24% lower with semaglutide 1.0 mg weekly than with placebo.
In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide lowered the risk of serious kidney problems by 24% compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseMajor kidney disease events (composite)
Study
n = 3,533
Comparator
Placebo
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg weekly · subcutaneous · median follow-up of 3.4 yearsAs given in this study (human).
Measurements
Hazard ratio
0.76
semaglutide vs placebo
Source sentences
Summary
The risk of a primary-outcome event was 24% lower in the semaglutide group than in the placebo group (331 vs. 410 first events; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003).
2 context sentences(design, population, supporting numbers)
Summary · context
receive subcutaneous semaglutide at a dose of 1.0 mg weekly or placebo.
Summary · context
Among the 3533 participants who underwent randomization (1767 in the semaglutide group and 1766 in the placebo group), median follow-up was 3.4 years, after early trial cessation was recommended at a prespecified interim analysis.
Report a problemFND-3878520901
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and chronic kidney disease, the mean annual eGFR slope was less steep with semaglutide than with placebo, indicating a slower decrease.
In plain wordsIn adults with type 2 diabetes and kidney disease, kidney function declined more slowly on semaglutide than on placebo.
Peptide
Semaglutide
Outcome
IncreaseAnnual eGFR slope
Study
n = 3,533
Comparator
Placebo
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg weekly · subcutaneous · median follow-up of 3.4 yearsAs given in this study (human).
Measurements
Difference in annual eGFR slope
1.16 ml per minute per 1.73 m2
semaglutide vs placebo
Source sentences
Summary
the mean annual eGFR slope was less steep (indicating a slower decrease) by 1.16 ml per minute per 1.73 m² in the semaglutide group (P<0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
receive subcutaneous semaglutide at a dose of 1.0 mg weekly or placebo.
Summary · context
Among the 3533 participants who underwent randomization (1767 in the semaglutide group and 1766 in the placebo group), median follow-up was 3.4 years, after early trial cessation was recommended at a prespecified interim analysis.
Report a problemFND-3878520904
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and chronic kidney disease, the risk of major cardiovascular events was 18% lower with semaglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide lowered the risk of major heart and blood vessel events by 18% compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseMajor cardiovascular events
Study
n = 3,533
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1.0 mg weekly · subcutaneous · median follow-up of 3.4 yearsAs given in this study (human).
Measurements
Hazard ratio
0.82
semaglutide vs placebo
Source sentences
Summary
the risk of major cardiovascular events 18% lower (hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = 0.029
2 context sentences(design, population, supporting numbers)
Summary · context
receive subcutaneous semaglutide at a dose of 1.0 mg weekly or placebo.
Summary · context
Among the 3533 participants who underwent randomization (1767 in the semaglutide group and 1766 in the placebo group), median follow-up was 3.4 years, after early trial cessation was recommended at a prespecified interim analysis.
Report a problemFND-3878520905
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and chronic kidney disease, the risk of death from any cause was 20% lower with semaglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide lowered the risk of death from any cause by 20% compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseDeath from any cause
Study
n = 3,533
Comparator
Placebo
Analysis
Secondary
Outcome group
Mortality · Whole body
Studied dose
1.0 mg weekly · subcutaneous · median follow-up of 3.4 yearsAs given in this study (human).
Measurements
Hazard ratio
0.8
semaglutide vs placebo
Source sentences
Summary
the risk of death from any cause 20% lower (hazard ratio, 0.80; 95% CI, 0.67 to 0.95, P = 0.01
2 context sentences(design, population, supporting numbers)
Summary · context
receive subcutaneous semaglutide at a dose of 1.0 mg weekly or placebo.
Summary · context
Among the 3533 participants who underwent randomization (1767 in the semaglutide group and 1766 in the placebo group), median follow-up was 3.4 years, after early trial cessation was recommended at a prespecified interim analysis.
Report a problemFND-3878520906
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and chronic kidney disease, the kidney-specific composite of the primary outcome was lower with semaglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide lowered the risk of kidney-specific problems compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseKidney-specific components of the primary composite
Study
n = 3,533
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg weekly · subcutaneous · median follow-up of 3.4 yearsAs given in this study (human).
Measurements
Hazard ratio
0.79
semaglutide vs placebo
Source sentences
Summary
Results were similar for a composite of the kidney-specific components of the primary outcome (hazard ratio, 0.79; 95% CI, 0.66 to 0.94)
2 context sentences(design, population, supporting numbers)
Summary · context
receive subcutaneous semaglutide at a dose of 1.0 mg weekly or placebo.
Summary · context
Among the 3533 participants who underwent randomization (1767 in the semaglutide group and 1766 in the placebo group), median follow-up was 3.4 years, after early trial cessation was recommended at a prespecified interim analysis.
Report a problemFND-3878520902
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and chronic kidney disease, the risk of death from cardiovascular causes was lower with semaglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide lowered the risk of dying from heart and blood vessel causes compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseDeath from cardiovascular causes
Study
n = 3,533
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
1.0 mg weekly · subcutaneous · median follow-up of 3.4 yearsAs given in this study (human).
Measurements
Hazard ratio
0.71
semaglutide vs placebo
Source sentences
Summary
for death from cardiovascular causes (hazard ratio, 0.71; 95% CI, 0.56 to 0.89).
2 context sentences(design, population, supporting numbers)
Summary · context
receive subcutaneous semaglutide at a dose of 1.0 mg weekly or placebo.
Summary · context
Among the 3533 participants who underwent randomization (1767 in the semaglutide group and 1766 in the placebo group), median follow-up was 3.4 years, after early trial cessation was recommended at a prespecified interim analysis.
Report a problemFND-3878520903
07HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and chronic kidney disease, serious adverse events were reported in a lower percentage of participants with semaglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and kidney disease, fewer people on semaglutide than on placebo had serious side effects.
Peptide
Semaglutide
Outcome
DecreaseSerious adverse events
Study
n = 3,533
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
1.0 mg weekly · subcutaneous · median follow-up of 3.4 yearsAs given in this study (human).
Measurements
Participants with serious adverse events
49.6%
semaglutide
Participants with serious adverse events
53.8%
placebo
Source sentences
Summary
Serious adverse events were reported in a lower percentage of participants in the semaglutide group than in the placebo group (49.6% vs. 53.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
receive subcutaneous semaglutide at a dose of 1.0 mg weekly or placebo.
Summary · context
Among the 3533 participants who underwent randomization (1767 in the semaglutide group and 1766 in the placebo group), median follow-up was 3.4 years, after early trial cessation was recommended at a prespecified interim analysis.
Report a problemFND-3878520907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 2 ongoing · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

Enrolling by invitationPhase 4NCT07547878

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Baylor Research Instituten = 648 Apr 2026 to est. 31 Mar 2029

Chronic Kidney Disease · Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 13 Oct 2026

RecruitingPhase not statedNCT07309094

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Cardenal Herrera Universityn = 25015 Sept 2023 to est. 31 Dec 2028

Chronic Kidney Disease stage3 · Chronic Kidney Disease stage4 · Chronic Kidney Disease Stage 1 · Chronic Kidney Disease Stage 2 · Obesity · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 30 Dec 2025

CompletedPhase 3Results postedNCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Novo Nordisk A/Sn = 3,53317 Jun 2019 to 9 Jan 2024

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 20 Mar 2025

CompletedPhase not statedResults postedNCT07465926

Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

Chung Shan Medical Universityn = 451,0361 Jan 2017 to 31 Jan 2026

Cardiovascular-kidney-metabolic Syndrome · Cardiovascular Disease Risk Factor · Kidney Disease · Type 2 Diabetes · Obesity & Overweight

Trial page ClinicalTrials.govUpdated 22 Jun 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.